1. Ubiquitin C-terminal hydrolase-L1 expression in non-small-cell lung cancer and its association with clinicopathological features and prognosis
- Author
-
Ping-Li Sun, Meng Jia, Jiaqi Yu, Shili Yu, and Hongwen Gao
- Subjects
Lung Neoplasms ,Cell ,Ubiquitin C-Terminal Hydrolase ,Adenocarcinoma ,B7-H1 Antigen ,Pathology and Forensic Medicine ,Ubiquitin ,Carcinoma, Non-Small-Cell Lung ,PD-L1 ,Biomarkers, Tumor ,Humans ,Medicine ,Lung cancer ,Molecular Biology ,Pathological ,biology ,business.industry ,Hazard ratio ,Cell Biology ,General Medicine ,medicine.disease ,medicine.anatomical_structure ,Cancer research ,biology.protein ,business ,Ubiquitin Thiolesterase - Abstract
UbiquitinC-terminal hydrolase-L1 (UCH-L1) is a cysteine hydrolase. It functions as a ubiquitin hydrolase, stabilizes the ubiquitin monomer, and affects cell division through cell cycle protein deubiquitination. Abnormal UCH-L1 expression is closely related to the occurrence and development of several tumors. Although some in vitro studies have demonstrated the significance of UCH-L1 in non-small-cell lung cancer (NSCLC), only few clinical studies have focused on the UCH-L1 expression in NSCLC, and the results are controversial and non-uniform. We investigated the UCH-L1 expression in 401 cases of surgically resected NSCLC, including 286 cases of adenocarcinoma (ADC) and 65 cases of squamous cell carcinoma. The associations between the UCH-L1 expression and clinicopathological features, programmed cell death-ligand 1 (PD-L1) expression, and prognostic significance were analyzed. For NSCLC, the UCH-L1 expression is associated with sex, smoking history, tumor size (>3 cm), lymphocyte infiltration, advanced pathological stages, and shortened overall survival (OS; 89.72 vs. 114.55 months; P = 0.005), but not PD-L1 expression. The UCH-L1 expression in ADC is associated with advanced pathological stages, pleural invasion, and shortened OS (90.38 vs. 118.55 months; P = 0.010). Multivariate analysis confirmed that UCH-L1 expression was an independent poor prognostic factor for NSCLC (OS: hazard ratio [HR], 1.854; 95% confidence interval [CI], 1.132-3.038; P = 0.014). Our results suggest that the UCH-L1 expression differs across tumors with different clinicopathological features, and it is related to poor prognosis.
- Published
- 2021